Femoston conti

Medicinal product

(Invented) name

Femoston conti

Active substance (s)

Estradiolis/Didrogesteronas

Strength

0,5 mg/2,5 mg

Pharmaceutical form

plėvele dengtos tabletės

Route (s) of administration

vartoti per burną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

G03FA14, Dydrogesterone and estrogen

Marketing authorisation holder

MagnaPharm SK s. r. o., Slovakija

Date of authorisation

2010-07-29

Date of renewal

2015-04-22

Documents

2108 Femoston conti 0,5_2,5 PCS PL 2024 11 12.docx

2108 Pakuotės lapelis 2024 11 12.docx

Stage

Perregistruotas

Controlled?

No

Controlled substance type

Legal basis

8(3)

Procedure number

NL/H/2280/002

Marketing authorisation procedure

Decentralizuota procedūra

Qualitative and quantitative composition

Tabletėje yra	1 vnt.
Estradiolis	0,5 mg
Didrogesteronas	2,5 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
42162	55927	1055927	lizdinė plokštelė	N28		Receptinis	LT/1/10/2108/002	Tiekiama	-	-	No	-	-	Download
42163	55928	1055928	lizdinė plokštelė	N84		Receptinis	LT/1/10/2108/003	Netiekiama	-	-	No	-	-
42164	55929	1055929	lizdinė plokštelė	N280		Receptinis	LT/1/10/2108/004	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2015-04-22	Perregistruotas
2010-07-29	Registruotas